Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Retained Earnings (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Retained Earnings for 9 consecutive years, with $36000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 100.0% year-over-year to $36000.0, compared with a TTM value of $36000.0 through Dec 2025, up 100.0%, and an annual FY2025 reading of $36000.0, up 100.0% over the prior year.
  • Retained Earnings was $36000.0 for Q4 2025 at Puma Biotechnology, up from -$1.3 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $36000.0 in Q4 2025 and bottomed at -$1.4 billion in Q1 2022.
  • Average Retained Earnings over 5 years is -$1.0 billion, with a median of -$1.3 billion recorded in 2021.
  • The sharpest move saw Retained Earnings crashed 132631000.0% in 2021, then surged 100.0% in 2025.
  • Year by year, Retained Earnings stood at -$1.4 billion in 2021, then increased by 0.0% to -$1.4 billion in 2022, then increased by 1.58% to -$1.3 billion in 2023, then rose by 2.25% to -$1.3 billion in 2024, then soared by 100.0% to $36000.0 in 2025.
  • Business Quant data shows Retained Earnings for PBYI at $36000.0 in Q4 2025, -$1.3 billion in Q3 2025, and -$14000.0 in Q2 2025.